Lifeline Biotechnologies Inc (LLBO)

[SquirrelCage]

Mm-hmm. And I guess the same thing can be said for the projections in the "near future". We'll believe it when we see it. Their testing showed it was much better at late stage (III) cancer, and even then, was less accurate than the success rate of the iTbra. Maybe better for targeted therapy than detection.

"CancerSEEK is not yet available to the public, and it probably won't be for a year or longer, Papadopoulos said.

"We are still evaluating the test, and it hasn't been commercialized yet," he said. "I don't want to guess when it will be available, but I hope it is soon."

He said that eventually the test could cost less than $500 to run and could easily be administered by a primary care physician's office.